Specifically, the activated TFs included MAF in C0 IGLL5+ Myeloma Cells, LEF1 in C1 IGHG4+ Myeloma Cells, TCF12 in C2 MALAT1+ Myeloma Cells, and CREB5 in C3 IGHG1+ Myeloma Cells (Figure 8A). This evidence concerns the gene MALAT1 and plasma cell myeloma.